Ex Parte Naber et al - Page 19



                Appeal 2006-2468                                                                             
                Application 10/149,875                                                                       

                Cir. 1999) (determining that a prior art disclosure of, e.g., “33-80%” or “50-               
                70%” constitutes a description of “60-90%” for a component of a claimed                      
                composition).                                                                                
                      We note that the holding in Atofina was based on a significantly                       
                different record than the record before us in this appeal.  In Atofina, 441 F.3d             
                at 999, 78 U.S.P.Q.2d at 1423-24,  the U.S. Court of Appeals for the Federal                 
                Circuit reversed an anticipation determination of  a district court (United                  
                States District Court for the District of Delaware) because of  a                            
                misapplication of Titanium Metals Corp. v. Banner, 778 F.2d 775, 782,                        
                227 U.S.P.Q. 773, 779 (Fed. Cir. 1985).  In reversing, the court held that                   
                “Titanium Metals stands for the proposition that an earlier species reference                
                anticipates a later genus claim, not that an earlier genus anticipates narrower              
                species.”  Atofina, 441 F.3d at 999, 78 U.S.P.Q.2d at 1424.  However, the                    
                court, in Atofina, 441 F.3d at 999, 78 U.S.P.Q.2d at 1423, made it clear that                
                a small genus can anticipate a species of that genus, even where the                         
                anticipated species is not mentioned in the anticipating reference and the                   
                court referenced several earlier decisions consonant with this proposition (In               
                re Petering, 301 F.2d at 682, 133 U.S.P.Q. at 281 (CCPA 1962) and Bristol-                   
                Meyers Squibb, Co. v. Ben Venue Labs., Inc., 246 F.3d 1368, 1380,                            
                58 U.S.P.Q.2d 1508).                                                                         
                      While the court made several observations about slightly overlapping                   
                or subsumed ranges and range endpoints in Atofina, 441 F.3d at 999-1000,                     
                78 U.S.P.Q.2d at 1424, it must be kept in mind that those observations were                  

                                                        19                                                   




Page:  Previous  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  Next 

Last modified: November 3, 2007